Citius Pharmaceuticals : Signs an Exclusive Worldwide Licensing Agreement with Novellus Therapeutics for Unique iMSC-Therapy – marketscreener.com
stemadminMesenchymal Stem CellsNo comments

CRANFORD - Citius Pharmaceuticals, Inc. ('Citius' or the 'Company') (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, announced that it has signed an exclusive agreement with Novellus Therapeutics Limited ('Novellus') to license iPSC-derived mesenchymal stem cells (iMSCs), and has created a new subsidiary, NoveCite, that will be focused on developing cellular therapies. NoveCite has a worldwide exclusive license from Novellus, an engineered cellular medicines company, to develop and commercialize NoveCite mesenchymal stem cells ('NC-iMSCs') to treat acute respiratory conditions with a near term focus on Acute Respiratory Distress Syndrome ('ARDS') associated with COVID-19

Read more
Global Mesenchymal Stem Cells by leading manufacturers with its application and types 2020-2026| Lonza, Celprogen, ATCC – re:Jerusalem
stemadminMesenchymal Stem CellsNo comments

Mesenchymal Stem Cells Market Report Delivering Growth Analysis with Key Trends of Top Companies (2020-2026) A comprehensive research study on the Mesenchymal Stem Cells Marketwas recently published by Market Report Expert. This is an up-to-date report, covering the current COVID-19 impact on the market. The Coronavirus (COVID-19) has affected every aspect of life globally and thus altering the global market scenario

Read more
Citius Pharma inks license pact with Novellus for stem cell therapy in respiratory distress – Seeking Alpha
stemadminMesenchymal Stem CellsNo comments

Citius Pharmaceuticals (NASDAQ:CTXR) has exercised its previously announced option agreement, andannounced an exclusive agreement with Novellus Therapeutics to license iPSC-derived mesenchymal stem cells (iMSCs). The company has created a new subsidiary, NoveCite, that will focus on development and commercialization of NoveCite mesenchymal stem cells (NC-iMSCs) for the treatment of acute respiratory conditions with a near term focus on Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19.

Read more
FibroGenesis Expands Fight Against COVID-19 In Brazil with International Collaboration – PRNewswire
stemadminMesenchymal Stem CellsNo comments

HOUSTON, Oct. 1, 2020 /PRNewswire/ -- FibroGenesis, the leading developer of fibroblast based therapeutic solutions for unmet medical needs has entered into a clinical collaboration agreement with Brazilian R4D Biotech.Holding the world's largest patent portfolio in the field of cell therapies using fibroblasts, FibroGenesis is expanding its ongoing clinical programs internationally. The partnership will pave the way for clinical studies of PneumoBlast in Brazil as a unique treatment of acute respiratory distress syndrome (ARDS) for patients affected by COVID-19, in parallel to clinical studies in the United States upon approval by the FDA

Read more
Global Mesenchymal Stem Cells Market 2015-2025 In-Depth Analysis, CO-VID 19 Impact on Industry Demands, Trends, Sales and Applications|Lonza, Thermo…
stemadminMesenchymal Stem CellsNo comments

Competitive Market Research Report on Global Mesenchymal Stem Cells Market with focus on Industry Analysis, Applications, Demands, Growth Projections, Development Status, Competitive Landscape, Investments, Top Business Players and Regional Forecasts by 2025. This research report contains an in-depth information on all the key aspects of the global Mesenchymal Stem Cells market

Read more

Theme: Illdy.